68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

被引:101
|
作者
Sathekge, Mike [1 ,2 ]
Lengana, Thabo [1 ,2 ]
Modiselle, Moshe [1 ,2 ]
Vorster, Mariza [1 ,2 ]
Zeevaart, JanRijn [1 ,2 ]
Maes, Alex [1 ,2 ,3 ]
Ebenhan, Thomas [1 ,2 ]
Van de Wiele, Christophe [1 ,2 ,4 ]
机构
[1] Univ Pretoria, Dept Nucl Med, Private Bag X169, ZA-0001 Pretoria, South Africa
[2] Steve Biko Acad Hosp, Private Bag X169, ZA-0001 Pretoria, South Africa
[3] AZ Groeninge, Dept Nucl Med, Kortrijk, Belgium
[4] Univ Ghent, Dept Radiol & Nucl Med, Ghent, Belgium
关键词
Ga-68-PSMA; PET/CT; Breast cancer; POSITRON-EMISSION-TOMOGRAPHY; ADVANCED SOLID TUMORS; FACTOR RECEPTOR 2; PROSTATE-CANCER; PSMA EXPRESSION; FDG PET; ANGIOGENESIS; METASTASES; THERAPY;
D O I
10.1007/s00259-016-3563-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To report on imaging findings using Ga-68-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients. Ga-68-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. Out of 81 tumor lesions identified, 84% were identified on Ga-68-PSMA-HBED-CC PET. Ga-68-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptor-negative lesions. SUV values derived from FDG PET/CT, available in seven patients, and Ga-68-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p = 0.015). Ga-68-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.
引用
收藏
页码:689 / 694
页数:6
相关论文
共 50 条
  • [41] Prospective evaluation of medium and high risk prostate cancer patients at initial staging with (18F)AlF-PSMA-HBED-CC: Intraindividual comparison with 68Ga-PSMA-HBED-CC
    Alonso Nunez, O.
    dos Santos, G.
    Rodriguez Taroco, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S458 - S458
  • [42] Preparation and chemical analysis of clinical-grade 68Ga-PSMA-HBED-CC, an emerging tracer for imaging of prostate cancers.
    Schneider, Bernadette
    Zhu, Hua
    Ma, Xiaowei
    Cheng, Zhen
    Iagaru, Andrei
    Kopka, Klaus
    Chin, Frederick
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [43] Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
    Dietlein, Markus
    Kobe, Carsten
    Kuhnert, Georg
    Stockter, Simone
    Fischer, Thomas
    Schomaecker, Klaus
    Schmidt, Matthias
    Dietlein, Felix
    Zlatopolskiy, Boris D.
    Krapf, Philipp
    Richarz, Raphael
    Neubauer, Stephan
    Drzezga, Alexander
    Neumaier, Bernd
    MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (04) : 575 - 584
  • [44] Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
    Markus Dietlein
    Carsten Kobe
    Georg Kuhnert
    Simone Stockter
    Thomas Fischer
    Klaus Schomäcker
    Matthias Schmidt
    Felix Dietlein
    Boris D. Zlatopolskiy
    Philipp Krapf
    Raphael Richarz
    Stephan Neubauer
    Alexander Drzezga
    Bernd Neumaier
    Molecular Imaging and Biology, 2015, 17 : 575 - 584
  • [45] 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study
    Lengana, Thabo
    van de Wiele, Christophe
    Lawal, Ismaheel
    Maes, Alex
    Ebenhan, Thomas
    Boshomane, Tebatso
    Zeevaart, Jan R.
    Ankrah, Alfred
    Mokgoro, Neo
    Vorster, Mariza
    Sathekge, Mike
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (02) : 179 - 185
  • [46] Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer
    Pfob, Christian H.
    Ziegler, Sibylle
    Graner, Frank Philipp
    Koehner, Markus
    Schachoff, Sylvia
    Blechert, Birgit
    Wester, Hans-Juergen
    Scheidhauer, Klemens
    Schwaiger, Markus
    Maurer, Tobias
    Eiber, Matthias
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (11) : 1962 - 1970
  • [47] Integrated 68Ga-HBED-CC-PSMA-PET/MRI in patients with suspected recurrent prostate cancer
    Luetje, Susanne
    Cohnen, Joseph
    Gomez, Benedikt
    Grueneisen, Johannes
    Sawicki, Lino M.
    Ruebben, Herbert
    Bockisch, Andreas
    Umutlu, Lale
    Poeppel, Thorsten D.
    Wetter, Axel
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2017, 56 (03): : 73 - 81
  • [48] Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT
    Verma, Priyanka
    Malhotra, Gaurav
    Agrawal, Ritesh
    Sonavane, Sunita
    Meshram, Vilas
    Asopa, Ramesh V.
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (08) : E265 - E268
  • [49] PET/CT evaluation of prostate cancer patients with Al18F-PSMA-HBED-CC: a head-to-head comparison with 68Ga-PSMA-HBED-CC.
    Alonso, Omar
    dos Santos, Gerardo
    Giglio, Javier
    Savio, Eduardo
    Engler, Henry
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [50] 68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study
    Martinez, Juana
    Subramanian, Kritika
    Margolis, Daniel
    O'Dwyer, Elisabeth
    Osborne, Joseph
    Jhanwar, Yuliya
    Nagar, Himanshu
    Williams, Nicholas
    RoyChoudhury, Arindam
    Madera, Gabriela
    Babich, John
    Castellanos, Sandra Huicochea
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):